- Home
- CRBP vs BKN Comparison
CRBP vs BKN Comparison
Compare CRBP & BKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- BKN
- Stock Information
- Founded
- CRBP 2009
- BKN 1992
- Country
- CRBP United States
- BKN United States
- Employees
- CRBP N/A
- BKN N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- BKN Trusts Except Educational Religious and Charitable
- Sector
- CRBP Health Care
- BKN Finance
- Exchange
- CRBP Nasdaq
- BKN Nasdaq
- Market Cap
- CRBP 227.3M
- BKN 209.9M
- IPO Year
- CRBP N/A
- BKN N/A
- Fundamental
- Price
- CRBP $16.73
- BKN $11.93
- Analyst Decision
- CRBP Strong Buy
- BKN
- Analyst Count
- CRBP 7
- BKN 0
- Target Price
- CRBP $65.86
- BKN N/A
- AVG Volume (30 Days)
- CRBP 346.4K
- BKN 55.5K
- Earning Date
- CRBP 11-07-2024
- BKN 01-01-0001
- Dividend Yield
- CRBP N/A
- BKN 4.38%
- EPS Growth
- CRBP N/A
- BKN N/A
- EPS
- CRBP N/A
- BKN N/A
- Revenue
- CRBP N/A
- BKN N/A
- Revenue This Year
- CRBP N/A
- BKN N/A
- Revenue Next Year
- CRBP N/A
- BKN N/A
- P/E Ratio
- CRBP N/A
- BKN N/A
- Revenue Growth
- CRBP N/A
- BKN N/A
- 52 Week Low
- CRBP $4.00
- BKN $9.57
- 52 Week High
- CRBP $61.90
- BKN $12.69
- Technical
- Relative Strength Index (RSI)
- CRBP 37.25
- BKN 29.22
- Support Level
- CRBP $15.65
- BKN $12.20
- Resistance Level
- CRBP $17.18
- BKN $12.38
- Average True Range (ATR)
- CRBP 1.26
- BKN 0.13
- MACD
- CRBP 0.35
- BKN -0.02
- Stochastic Oscillator
- CRBP 21.09
- BKN 7.94
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About BKN BlackRock Investment Quality Municipal Trust Inc. (The)
Blackrock Investment Quality Municipal Trust, Inc. is a closed-end management investment fund with the investment objective to provide high current income exempt from regular U.S. federal income tax consistent with the preservation of capital.